Uncovering clinically relevant phenotypic variations in malignancies: CD23 in mantle cell lymphoma

American Journal of Clinical Pathology

Volumn 130, Issue 2, 2008, Pages 159-161

  Kroft, Steven H ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD23 ANTIGEN;

CHRONIC LYMPHATIC LEUKEMIA; EDITORIAL; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; MANTLE CELL LYMPHOMA; MICROENVIRONMENT; MULTIVARIATE ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

FLOW CYTOMETRY; HUMANS; LYMPHOMA, MANTLE-CELL; PHENOTYPE; PROGNOSIS; RECEPTORS, IGE;

EID: 48649092279     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/FTEP3KEXW7T2UEXY     Document Type: Editorial

References (19)

1. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
2. Jaffe ES, Harris NL, Stein H, et al, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001. World Health Organization Classification of Tumours.
3. Banks PM, Chan J, Cleary ML, et al. Mantle cell lymphoma; a proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol. 1992;16:637-640.
4. Swerdlow SH, Zukerberg LR, Yang WI, et al. The morphologic spectrum of non-Hodgkin's lymphomas with BCL1/cyclin D1 gene rearrangements. Am J Surg Pathol. 1996;20:627-640.
5. Wong KF, So CC, Chan JK. Nucleolated variant of mantle cell lymphoma with leukemic manifestations mimicking prolymphocytic leukemia. Am J Clin Pathol. 2002;117:246-251.
6. Kelemen K, Peterson LC, Helenowski I, et al. CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- disease. Am J Clin Pathol. 2008;130:166-177.
7. Liu Z, Dong HY, Gorczyca W, et al. CD5- mantle cell lymphoma. Am J Clin Pathol. 2002;118:216-224.
8. Camacho FI, Garcia JF, Cigudosa JC, et al. Aberrant bcl6 protein expression in mantle cell lymphoma. Am J Surg Pathol. 2004;28:1051-1056.
9. Viswanatha DS, Foucar K, Berry BR, et al. Blastic mantle cell leukemia: an unusual presentation of blastic mantle cell lymphoma. Mod Pathol. 2000;13:825-833.
10. Rubio-Moscardo F, Climent J, Siebert R, et al. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood. 2005;105:4445-4454.
11. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3:185-197.
12. Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1-negative mantle cell lymphoma: a study of nine cases [abstract]. Mod Pathol. 2004;17(suppl 1):248A.
13. Schlette E, Fu K, Medeiros LJ. CD23 expression in mantle cell lymphoma: clinicopathologic features of 18 cases. Am J Clin Pathol. 2003;120:760-766.
14. Gong JZ, Lagoo AS, Peters D, et al. Value of CD23 determination by flow cytometry in differentiating mantle cell lymphoma from chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Clin Pathol. 2001;116:893-897.
15. Chen Y-H, Peterson LC, Dittmann D, et al. Comparative analysis of flow cytometric techniques in assessment of ZAP-70 expression in relation to IgVH mutational status in chronic lymphocytic leukemia. Am J Clin Pathol. 2007;127:182-191.
16. Ghia P, Guida G, Stella S, et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood. 2003;101:1262-1269.
17. Geisler CH, Larsen JK, Hansen NE, et al. Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. Blood. 1991;78:1795-1802.
18. Dadmarz R, Cawley JC. Heterogeneity of CLL: high CD23 antigen and alpha IFN receptor expression are features of favourable disease and of cell activation. Br J Haematol. 1988;68:279-282.
19. Byrd JC, O'Brien S, Flinn IW, et al. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2007;13:4448-4455.